Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-06-24
Item 5.02
Ryan Cotterman was appointed as Vice President, Chief Accounting Officer and principal accounting officer of Ingevity Corporation on June 22, 2026. The disclosure centers on the appointment of a named executive officer to a principal accounting role, with detailed compensation terms including base salary ($345,000), bonus target (40%), long-term incentive opportunity (65%), sign-on bonus ($40,000), and equity award ($150,000 RSUs). This is a material executive appointment affecting the registrant's accounting leadership and financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-24
Item 5.02
Robin Schulman, Chief Legal Officer, Head of Corporate Affairs, and Corporate Secretary, resigned effective June 30, 2026, representing a departure of a named executive officer holding multiple senior leadership roles.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
GitLab held its Annual Meeting of Stockholders on June 17, 2026, with shareholders voting on three proposals: election of two Class II directors (Karen Blasing and Godfrey Sullivan), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →
6-K
M&A activity
confidence 99%
filed 2026-06-24
GSK announces commencement of a tender offer to acquire all outstanding shares of Nuvalent, Inc. for $124.00 per share pursuant to an Agreement and Plan of Merger dated June 9, 2026. This is a material acquisition transaction involving a direct wholly-owned subsidiary of GSK acquiring a NASDAQ-listed biopharmaceutical company, with the Nuvalent Board recommending stockholder acceptance of the offer.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
Absci announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201, a novel antibody candidate. The disclosure highlights favorable safety findings, pharmacokinetic profile (estimated half-life of at least 65 days), and advancement to the multiple ascending dose phase. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The event is clearly operational/strategic in nature—a significant clinical trial milestone—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-24
Item 4.01
The filing discloses a mutual termination of Stephano Slack LLC as the Company's independent registered public accounting firm on June 18, 2026, and the concurrent engagement of M&K, CPA's LLC as the successor auditor. The prior auditor's report contained an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern, which constitutes a reportable event. This is a classic auditor change under Item 4.01 and is material to investors given the going-concern qualification in the prior audit.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-24
Item 1.01
Lemonade entered into a New Business Financing Agreement with Hannover Re providing up to $250 million in outstanding capital for sales and marketing growth efforts through 2028, structured as a financing facility with repayment terms based on premium collections and a specified rate of return (three-year Treasury Bill rate plus 5.8%).
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-06-24
Item 2.05
Elastic disclosed a committed plan on June 23, 2026 to reduce workforce by approximately 7% as part of organizational restructuring to align with AI automation priorities, with non-recurring cash charges of $22–25 million primarily for severance and termination benefits, with implementation expected through Q3 fiscal 2027.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-24
Item 5.02
Ken Exner, Chief Product Officer, notified the Company on June 18, 2026 of his resignation effective July 17, 2026, resulting in organizational restructuring where engineering leaders will now report directly to the CEO.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
Serina Therapeutics held its 2026 Annual Meeting of Stockholders on June 17, 2026, with voting results disclosed covering eight proposals including director elections, authorization of additional common shares, equity plan amendment, preferred stock conversion, private placement securities exercise, say-on-pay votes, and auditor ratification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-24
EX-99.1
This press release announces Formind Global's entry into a student recruitment and support services agreement with City University Malaysia, marking the "first announced operating agreement" through the Company's Malaysia-based global headquarters platform and the "launch of the Company's international education and student support services initiative." While the agreement is commission-based with no guaranteed revenue, it represents a material operational milestone in the Company's stated strategic transition toward the Formind Group identity and international expansion. The disclosure does not fit discrete event categories (not M&A, not a material contract requiring Item 1.01 treatment, not a periodic report), but is clearly a significant operational and strategic development that would affect a reasonable investor's assessment of the Company's execution on its announced Formind strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 1.01
Quantum-Si entered into a 120-month lease agreement for approximately 54,374 square feet of office, laboratory, and manufacturing space in San Diego, commencing September 1, 2027, with initial monthly base rent of $315,369.20 (subject to 3% annual increases), a landlord tenant allowance of $17.1 million, and a security deposit of $2.1 million. This material operational commitment reflects the company's planned facility expansion and transition to support Proteus platform development and manufacturing capabilities.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-24
Item 5.02
The disclosure centers on amended and restated employment and change of control agreements for five named officers (Van Dyke, Langs, Bell, Speare, and Kallsen), updating their compensatory arrangements and severance terms to comply with new Virginia law effective July 1, 2026, and reflecting current base salaries and positions. This is a classic Item 5.02(e) compensatory arrangement disclosure, distinct from a departure or appointment, and material because it modifies severance, clawback, and restrictive covenant provisions for senior executives.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
This 8-K Item 5.07 discloses the results of Candel Therapeutics' Annual Meeting of Stockholders held on June 23, 2026. The filing reports voting outcomes for two proposals: (i) election of four Class II directors (Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci), all of whom were elected, and (ii) ratification of KPMG LLP as independent auditor, which was ratified. The detailed vote tallies for each director and the auditor ratification are provided, making this a clear shareholder vote results disclosure material to investors' understanding of board composition and audit oversight.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
The Item 8.01 disclosure centers on two operational events: (1) a CEO presentation at an industry conference on June 25, 2026, and (2) a $4 million U.S. Navy ADMACS Modernization Subcontract awarded to subsidiary SSI. The subcontract is the material event—it represents a significant new government contract that expands the company's Navy software portfolio and is explicitly characterized by management as strengthening the company's position and supporting organic growth. This is a material operational/business development event that does not fit the specific categories of M&A, debt, or other named types, making operational_other the appropriate classification.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-24
Item 6.04
The filing discloses a failure to make a required distribution correctly: the Certificate Administrator erroneously passed through a curtailment payment on the Coastal Grand Mall Mortgage Loan to Class B Certificateholders, resulting in an overpayment of $743,802.75. While Item 6.04 is titled "Failure to Make a Required Distribution," the substance here is a distribution error and overpayment recovery matter—a financial event involving the trust's payment obligations to certificateholders. This does not fit the specific categories of earnings, debt, dividend, or impairment, but is clearly a material financial matter affecting the trust's cash flows and certificateholder interests.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
The disclosure announces that a GSTX subsidiary has been awarded a $45 million tax credit for two planned California solar manufacturing projects. This is a material operational and strategic event — a significant government incentive that supports the company's manufacturing expansion plans — but does not fit neatly into the specific event categories (it is not M&A, debt, equity issuance, or a routine contract). The tax credit award is a material development affecting the company's capital position and project economics, warranting classification as operational_other.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-24
Item 3.02
The filing discloses an unregistered sale of equity securities totaling approximately $243.9 million across three share classes (Class I, S, and D) on June 1, 2026, exempt under Section 4(a)(2) and Regulations D and S. This is a classic dilutive private placement. The materiality is underscored by the substantial aggregate consideration and the disclosure that the company has raised approximately $7.3 billion cumulatively since inception through such continuous private offerings.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-24
Item 2.03
The Company amended its existing revolving credit facility through an amendment and lender joinder agreement, increasing available credit by $125 million to an aggregate of $1.225 billion for its subsidiaries. This expansion of the credit facility constitutes a material creation of new direct financial obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-24
Item 3.02
The Company completed an unregistered sale of approximately $281 million in equity securities across multiple share classes (Class I, U, D, and S shares) to investors on June 1, 2026, exempt under Section 4(a)(2) and Regulations D and S. This private placement is part of the Company's ongoing continuous offering structure and materially affects shareholder ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-24
Item 3.02
The filing discloses an unregistered sale of 961,171 common shares for $25,125,000 pursuant to Section 4(a)(2) and Regulation D/S under the Securities Act. This is a classic dilutive equity issuance by a closed-end fund raising capital through a private placement, which is material to existing shareholders as it increases share count and dilutes ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-24
Item 3.02
TPG Private Equity Opportunities, L.P. sold $99.2 million of unregistered limited partnership units on June 1, 2026, across multiple unit classes (Class I, S, and F) to third-party investors and through a feeder vehicle, pursuant to Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-24
Item 3.02
Carlyle Private Equity Partners Fund sold approximately $16.4 million in unregistered limited partnership units on June 1, 2026, pursuant to a continuous private offering under Section 4(a)(2) and Regulation D, diluting existing unitholders' ownership interests.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-23
Item 5.02
Emanuel "Manny" Chirico announced on June 22, 2026 that he will not stand for reelection to the Board of Directors at the 2026 Annual Meeting, effectively departing from his board role. Although he will serve through the remainder of his current term, the principal disclosed action is a director's departure. The filing explicitly states his decision was not due to disagreement, indicating a routine non-reelection rather than a forced removal, but it remains a material change in board composition.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-06-23
Item 1.01
FMC entered into a framework agreement to sell its Newark, Delaware property for approximately $114 million in gross proceeds, with the proceeds expected to be used to pay down debt. While this is a material asset disposition, it does not fit the specific `ma_activity` category (which typically covers acquisitions, mergers, or changes of control) nor the `debt_issuance` category. The transaction is a significant real estate sale with financial implications (debt reduction), making it a material financial event best classified as `financial_other`.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-06-23
Item 7.01
Imperial Oil announced renewal of a normal course issuer bid (NCIB) to repurchase up to 5% of outstanding shares (24.2 million shares) over 12 months, representing a flexible and tax-efficient return of capital to shareholders. The company explicitly states this reflects its "priority and capacity to return cash to shareholders" and describes the NCIB as a method of "distributing surplus liquidity to shareholders." While technically a share repurchase rather than a dividend, this is a material capital allocation decision that affects shareholder value and falls within the dividend_distribution category as a return of capital program.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-23
Item 2.03
IBM extended the maturity of two existing credit facilities totaling $10 billion—a $2.5 billion Three-Year Credit Agreement and a $7.5 billion Five-Year Credit Agreement—by one year each, materially extending the company's liquidity and refinancing runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-23
Item 2.02
This is a clear earnings release disclosing Kewaunee Scientific's financial results for fiscal year 2026 and Q4 ended April 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing full-year sales of $281.999 million (up 17.3%), net earnings of $9.618 million, and diluted EPS of $3.22, along with detailed segment results and balance sheet metrics. This is a standard quarterly/annual earnings disclosure material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-23
Item 2.02
Korn Ferry issued a press release on June 23, 2026 announcing fourth quarter and full fiscal year 2026 results (ended April 30, 2026), disclosing fee revenue of $2.9 billion (up 7% YoY), net income of $277.4 million with a 9.5% margin, and diluted EPS of $5.22. The press release is attached as Exhibit 99.1 and constitutes a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-23
Item 8.01
The filing discloses settlement of forward sale agreements under an ATM equity distribution program and underwritten forward sale agreements, resulting in the delivery of approximately 8.7 million shares of common stock and generating ~$672 million in gross proceeds. These forward sale agreements represent dilutive equity issuances that were previously entered into and are now being physically settled. The magnitude of shares issued and cash raised, combined with the disclosure of substantial remaining outstanding forward obligations (~11.1 million shares worth ~$915 million), constitutes a material capital-raising event affecting shareholder equity and ownership dilution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-23
Item 5.02
Nike announced the appointment of David M. Denton as Executive Vice President and Chief Financial Officer, effective August 17, 2026, replacing Matthew Friend. Denton's compensation package includes a $1.45M base salary, $11.5M long-term incentive target, and a $7.25M new-hire cash award.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-23
Item 5.02
The disclosure centers on amended and restated employment agreements for two named executives (Ryan R. Smith and Jamie M. Schnur) that modify their compensatory arrangements, including severance multiples, payment periods, and post-employment benefits. While the agreements also address termination conditions, the principal disclosed action is the modification of executive compensation terms—specifically reducing Mr. Smith's severance multiple from 3x to 2x base salary and shortening restrictive covenant periods from 36 to 24 months. This is a classic exec_compensation event under Item 5.02(e).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-23
Item 2.02
KB Home issued a press release on June 23, 2026 announcing its results of operations for the three months and six months ended May 31, 2026, disclosing revenues of $1.11 billion, diluted earnings per share of $0.43 for Q2, and net income of $60.8 million for the six-month period. This is a standard quarterly earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, and is material to investors assessing the company's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a clear disclosure of shareholder voting results from Axogen's 2026 annual meeting held on June 23, 2026. The filing reports final vote tabulations for three proposals: election of eight directors, ratification of Deloitte & Touche LLP as independent auditors, and an advisory vote on named executive officer compensation. This is a quintessential Item 5.07 disclosure and is material to investors as it reflects shareholder approval of board composition and auditor selection.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-23
Item 2.03
Jack in the Box completed issuance of $500 million in Series 2026-1 7.624% Fixed Rate Senior Secured Notes, Class A-2, and entered into a $150 million revolving Variable Funding Notes facility on June 23, 2026, to refinance and repay existing securitized debt obligations and clear near-term maturities.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-23
Item 2.02
Carnival Corporation issued a press release on June 23, 2026 disclosing second quarter 2026 financial results, including record net income of $537 million, record adjusted net income of $569 million (up over 20%), and record revenues of $6.7 billion. The filing explicitly states this is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed quarterly results, full-year 2026 guidance, and forward-looking statements typical of an earnings announcement.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-23
Item 1.01
Fastenal entered into a Second Amended and Restated Credit Agreement on June 18, 2026, renewing its revolving credit commitment to $835 million (with accordion options up to $1.335 billion) and extending the maturity to June 18, 2031. The company also amended its Master Note Agreement to extend the issuance period for senior promissory notes through June 18, 2031, representing material modifications to the company's direct financial obligations and credit facilities.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-23
Item 5.02
Dr. Daniel M. Skovronsky, a member of the Board of Directors, resigned effective immediately on June 17, 2026. The disclosure explicitly states the resignation was not due to disagreement or operational concerns, but the departure of a director is a material governance event affecting the composition of the board and investor assessment of leadership continuity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a clear disclosure of shareholder voting results from Century Casinos' 2026 Annual Meeting of Stockholders held on June 22, 2026. The filing presents final vote tallies on three proposals: election of two Class II directors (Peter Hoetzinger and Mitchell Etess), ratification of Ernst & Young LLP as independent auditor, and an advisory vote on named executive officer compensation. This is the quintessential Item 5.07 disclosure and directly matches the shareholder_vote_results event type.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-06-23
Item 2.03
Beazer Homes issued $400 million aggregate principal amount of 8.000% Senior Unsecured Notes due 2032 in a private placement on June 23, 2026. Net proceeds will be used to redeem $357.3 million of the company's 5.875% Senior Notes due 2027, effectively refinancing existing debt at a higher coupon rate.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
Dollar Tree held its 2026 Annual Meeting of Shareholders on June 16, 2026, with voting results on four matters: election of ten directors, advisory approval of named executive officer compensation, ratification of KPMG LLP as independent auditor, and a shareholder proposal on written consent rights.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-23
Item 8.01
The disclosure announces expiration of the Hart-Scott-Rodino waiting period for a previously-disclosed merger agreement between Cross Country Healthcare and KL Criss Cross Intermediate, LLC, satisfying a major closing condition. The filing also references a concurrent sale of the Company's locums business division to an affiliate of the acquirer. This constitutes material M&A activity—a change of control transaction with expected closing in Q3 2026 and a shareholder vote scheduled for July 16, 2026.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-23
Item 8.01
Rafa Oliveira, head of KDP's Coffee Operating Unit, has announced his intention to depart at the end of July 2026 to pursue an external Chief Executive Officer opportunity. The Board is searching for his replacement as future CEO of Global Coffee Co. following the company's planned separation into two entities in early 2027.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-06-23
Item 1.01
Clear Secure entered into Amendment No. 4 to its Credit Agreement, modifying the terms of an existing credit facility by reducing commitments from $100 million to $50 million, improving pricing through lower margins and fees, and extending the maturity date from June 28, 2026 to June 23, 2031. This material amendment extends the life of the debt facility and modifies the registrant's direct financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 72%
filed 2026-06-23
Item 8.01
Cable One announced an exchange offer whereby MBI Lenders holding ~33.4% of outstanding MBI Term Loans can exchange their existing debt for either a combination of cash and new first-lien "first out" term loans, or new first-lien "second out" term loans. This creates new direct financial obligations (the new term loans) in exchange for retiring existing debt, which constitutes a material debt restructuring and issuance of new debt instruments. While this could also be characterized as a debt refinancing or restructuring, the core event is the creation of new debt obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-23
Item 1.01
The filing discloses a material amendment to the Company's credit agreement that increases the maximum revolver amount to $130 million, extends the maturity date to June 17, 2031, and provides additional flexibility for unsecured debt incurrence. While this is technically an amendment to an existing credit facility rather than a new debt issuance, it materially expands the Company's borrowing capacity and financial flexibility, which is the hallmark of a debt_issuance event. The increased revolver size and extended maturity are material changes to the Company's direct financial obligations.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 95%
filed 2026-06-23
Item 1.05
The filing explicitly discloses a material cybersecurity incident under Item 1.05, describing unauthorized access to 8x8's Salesforce system via a compromised Klue third-party integration between June 11-12, 2026. The threat actor exfiltrated competitively sensitive customer information including contract details, sales notes, and contact information. Although the Company states the incident is "not expected to have a material impact" on operations or financial condition, the disclosure of data exfiltration involving customer information and the Company's determination that it is reportable under Item 1.05 clearly establishes this as a material cybersecurity incident requiring classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-06-23
Item 5.02
F5, Inc. appointed Gavin Munroe as a director effective June 17, 2026, with assignment to the Risk and Audit Committees. The appointment includes compensatory arrangements comprising an annual retainer of $60,000, committee fees of $20,000 each, and a restricted stock unit grant valued at $275,000.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-06-23
Item 2.02
FedEx Corporation disclosed its financial results for the fiscal quarter and year ended May 31, 2026, via a press release dated June 23, 2026, attached as Exhibit 99.1. The filing reports consolidated revenue of $25.0 billion and $94.7 billion for Q4 and full-year FY2026 respectively, with operating income, net income, and diluted EPS figures for both periods. The company also provided CY 2026 outlook with revenue growth forecasts and EPS guidance. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-23
EX-99.1
This press release announces a significant operational milestone: completion of cost analysis and engineering review of a wearable sensing platform prototype for the Department of National Defence, with achievement of target cost objectives (under $1000 CAD per unit, under 250 grams) and anticipated initial annual orders of approximately 5,000 units. The company is advancing to the next development phase and plans to submit the design to foreign militaries. This is a material operational/strategic development involving a substantial government contract opportunity, but does not fit the specific event categories (not M&A, not a financial result, not an executive change, not a material impairment or covenant breach).
View raw filing on EDGAR →